How to Get Praluent (Alirocumab) in West Virginia

What Praluent Is and Why West Virginia Patients Need It

Alirocumab is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that degrades LDL receptors on liver cells. Blocking PCSK9 keeps more receptors on the cell surface, which pulls more LDL cholesterol out of the bloodstream. The FDA approved alirocumab in July 2015 for adults with heterozygous familial hypercholesterolemia or clinical ASCVD who need additional LDL-C reduction beyond maximally tolerated statin therapy [1].

West Virginia has the second-highest rate of cardiovascular disease mortality in the United States, according to CDC data [2]. Roughly 1 in 250 people nationwide carry a pathogenic variant for heterozygous FH, and many go undiagnosed for years [3]. Both facts make access to a high-efficacy LDL-lowering agent like alirocumab particularly relevant for WV residents.

The landmark ODYSSEY OUTCOMES trial (N=18,924) demonstrated that alirocumab reduced major adverse cardiovascular events by 15% (HR 0.85; 95% CI 0.78, 0.93; P<0.001) in patients with acute coronary syndrome already on high-intensity statins, compared with placebo [4]. LDL-C dropped from a median baseline of 87 mg/dL to 48 mg/dL at 4 months in the alirocumab arm [4]. Patients whose LDL-C fell below 25 mg/dL showed a 24% relative risk reduction in all-cause mortality in a pre-specified analysis [4].

The ACC/AHA 2018 Cholesterol Guideline states: "In patients with very high-risk ASCVD, use of a PCSK9 inhibitor is reasonable when LDL-C remains 70 mg/dL or higher on maximally tolerated statin plus ezetimibe therapy" [5]. That threshold gives prescribers a clear on-ramp for initiating alirocumab conversations in high-risk WV patients.

Who Can Prescribe Praluent in West Virginia

Any licensed prescriber with full prescriptive authority in West Virginia may write for alirocumab. That includes MDs, DOs, nurse practitioners (NPs) with a collaborative practice agreement or full practice authority depending on specialty, and physician assistants (PAs) practicing under supervising physician agreements. NPs in West Virginia currently operate under reduced practice authority in most settings, meaning they require a collaborative agreement with an MD or DO [6]. PAs follow a similar oversight model under WV Code §30-3E [7].

Cardiologists and lipidologists most often initiate PCSK9 inhibitors. Primary care physicians and internists may also prescribe. In practice, payers frequently require the prescriber to document specialty training or to obtain a peer-to-peer review before they approve prior authorization. Telehealth providers licensed in West Virginia hold the same prescriptive authority as in-person clinicians for most medications, including biologics [8].

How Telehealth Prescribing Works for Praluent in WV

West Virginia permits telehealth prescribers to initiate and manage medications for patients they have evaluated via synchronous audio-video encounters. The state adopted an interstate telehealth framework consistent with the Federation of State Medical Boards model [8]. A prescriber does not need to be physically located in West Virginia, provided they hold an active WV medical license or practice under an applicable interstate compact.

For alirocumab specifically, the telehealth visit must include a review of current lipid labs, existing statin therapy, cardiovascular history, and any contraindications. The prescriber then sends the prescription electronically to a specialty pharmacy, not a retail chain, because alirocumab requires cold-chain storage and injection training. Most specialty pharmacies operating in WV offer shipment within 3, 7 business days after prior authorization clears.

Platforms such as HealthRX connect patients with board-certified cardiologists and internists who can evaluate WV residents via video, order required labs, and manage the prior authorization process, reducing the time between initial consult and first injection. Typical end-to-end timelines from telehealth visit to drug delivery in WV run 7 to 21 days, with the majority of delay attributable to insurance PA review rather than clinical or pharmacy steps.

Labs Required Before Starting Praluent

A fasting lipid panel is the minimum lab requirement before any prescriber in West Virginia initiates alirocumab. The ACC/AHA guideline recommends measuring a complete lipid panel to confirm LDL-C and non-HDL-C levels that justify PCSK9 inhibitor therapy [5]. Many payers also require documentation of the most recent LDL-C on maximally tolerated statin therapy, which is usually a 12-week or older result showing LDL-C at or above the payer's threshold (commonly 70 mg/dL for ASCVD or 100 mg/dL for FH).

Additional labs that support prior authorization and guide clinical decision-making include:

• A complete metabolic panel to assess hepatic and renal function
• Thyroid-stimulating hormone (TSH) to rule out hypothyroidism as a secondary cause of dyslipidemia [9]
• HbA1c or fasting glucose if metabolic syndrome is suspected [10]
• Lipoprotein(a) measurement, because Lp(a) elevation is an independent ASCVD risk factor and may support medical necessity [11]

Genetic testing confirming a pathogenic FH variant (in genes such as LDLR, APOB, or PCSK9) is not required for prescribing but significantly strengthens a prior authorization application, particularly for HoFH [3]. The FH Foundation and several academic centers in WV offer genetic screening programs [12].

After alirocumab initiation, a repeat fasting lipid panel at 4 to 8 weeks confirms the LDL-C response. ODYSSEY OUTCOMES showed that 89% of patients titrated to 150 mg every 2 weeks achieved LDL-C below 50 mg/dL [4]. If LDL-C drops below 25 mg/dL on the 150 mg dose, the prescriber may reduce to 75 mg [1].

Prior Authorization Requirements in West Virginia

Prior authorization for alirocumab is required by essentially every commercial insurer operating in West Virginia, including Highmark WV, Aetna, Cigna, UnitedHealthcare, and BlueCross BlueShield of WV. Medicare Part D plans follow CMS guidance and impose their own PA criteria. WV Medicaid does not cover alirocumab at this time [13].

Typical PA criteria across WV commercial payers include:

1. Diagnosis of HeFH, HoFH, or established ASCVD (recent MI, stroke, or peripheral artery disease).
2. Documentation of current maximally tolerated statin therapy, defined as the highest dose the patient can tolerate without unacceptable adverse effects.
3. LDL-C at or above the plan's threshold despite statin therapy (commonly 70 mg/dL for ASCVD, 100 mg/dL for FH).
4. Trial and failure or contraindication to ezetimibe (many plans require at least 3 months of ezetimibe at 10 mg daily).
5. Prescriber specialty confirmation or peer-to-peer review by a cardiologist or lipidologist.

The American College of Cardiology's 2019 Expert Consensus Decision Pathway explicitly criticized step therapy requirements that delay PCSK9 inhibitor access: "Requiring sequential trials of additional lipid-lowering agents before approving PCSK9 inhibitors places patients with very high-risk ASCVD at unnecessary risk" [14]. West Virginia does not have a state law specifically limiting step therapy for biologics in commercial plans as of 2025, though the federal Consolidated Appropriations Act imposes some step therapy protections in employer-sponsored plans [15].

PA approvals in WV typically run 7, 14 calendar days for initial decisions. Appeals for denied claims must be submitted within 60 days of the denial notice under WV Insurance Commission rules [16]. Peer-to-peer calls with the payer's medical director succeed in overturning denials roughly 40 to 60% of the time, based on published lipid specialist survey data [17].

How to Transfer an Existing Praluent Prescription to West Virginia

Patients relocating to West Virginia who already have an established alirocumab prescription can transfer it with minimal friction, provided the prescriber is licensed in WV or the patient establishes care with a new WV-licensed prescriber. Specialty pharmacies that ship nationally (such as CVS Specialty, Walgreens Specialty, and Accredo) can transfer the prescription to a WV delivery address without requiring a new prescription in most cases, as long as the existing prescription has remaining refills.

The new WV-based insurer may impose its own PA requirements even if the prior insurer had already approved the drug. Patients should request a PA continuity letter from their prior insurer and submit it alongside the new PA application to speed review. Prescribers can also submit a letter of medical necessity citing the ODYSSEY OUTCOMES mortality data [4] and the ACC/AHA guideline threshold language [5] to preempt denial.

503A Compounding Pharmacies and Alirocumab in West Virginia

Alirocumab is a biologic monoclonal antibody. It cannot be compounded at a 503A pharmacy in a clinically equivalent form. The FDA's definition of a biologic under the Biologics Price Competition and Innovation Act (BPCIA) means that 503A pharmacies, which are licensed to compound non-sterile and sterile preparations from bulk drug substances, cannot produce a legally compliant copy of alirocumab [18]. West Virginia does have licensed 503A pharmacies that compound other lipid-adjacent therapies such as niacin formulations or specific hormone preparations, but these are not substitutes for alirocumab.

Patients who encounter offers of "compounded PCSK9 inhibitors" should treat those offers with caution. No FDA-approved biosimilar for alirocumab existed as of mid-2025, though biosimilar pathways are under development [19]. The legitimate branded product (Praluent) and any future FDA-approved biosimilar remain the only legal options.

Cost and Copay Assistance for West Virginia Patients

The list price of Praluent is approximately $6,500 per year for the every-2-week regimen. Commercial insurance with prior authorization approval brings patient cost-sharing down substantially. Regeneron's MyPraluent Copay Card program allows eligible commercially insured patients to pay as little as $0 per month, with Regeneron covering up to $3,600 per year in copay costs [20].

Medicare and Medicaid patients are excluded from manufacturer copay programs by federal anti-kickback statute rules. For Medicare Part D patients, the Praluent Patient Assistance Program (PAP) may provide the drug at no cost if income thresholds are met. WV Medicaid does not currently cover alirocumab; patients on Medicaid should ask their prescriber about alternative LDL-lowering options such as evolocumab (Repatha), which also lacks WV Medicaid coverage, or bempedoic acid (Nexletol), which may have different formulary status.

The ODYSSEY OUTCOMES trial published a cost-effectiveness analysis suggesting alirocumab approaches $100,000 per quality-adjusted life year (QALY) at list price, but falls to $29,000 per QALY when rebated net pricing is applied [21]. That figure sits within the $50,000, $150,000 per QALY range commonly cited as cost-effective in U.S. health economics literature [21].

Step-by-Step: How to Get Your First Praluent Prescription in WV

The following pathway reflects the HealthRX clinical team's experience coordinating alirocumab access for patients across rural and urban West Virginia counties.

Step 1. Confirm eligibility. You need either a confirmed or clinically suspected FH diagnosis (Dutch Lipid Clinic Network score of 6 or above is widely accepted [3]) or a documented history of MI, stroke, ACS, or peripheral artery disease combined with LDL-C at or above 70 mg/dL on maximally tolerated statin therapy.

Step 2. Get a current fasting lipid panel. Quest Diagnostics and LabCorp both operate collection sites across WV, including in Charleston, Huntington, Morgantown, Parkersburg, and Beckley. Many telehealth platforms can order labs directly to a nearby draw site. Results typically return within 24 to 48 hours.

Step 3. Schedule a prescriber visit. Book an in-person appointment with a cardiologist or lipidologist, or complete a telehealth visit with a WV-licensed prescriber. The visit should take 20 to 40 minutes and will cover your cardiovascular history, current medications, and lab results.

Step 4. Begin prior authorization. Your prescriber's office or the telehealth platform's PA team submits documentation to your insurer. Gather your most recent 3 to 6 months of statin prescription records and any ezetimibe trial documentation before the visit to speed this step.

Step 5. Enroll in the MyPraluent Copay Card. Your prescriber or the specialty pharmacy can enroll you at the time the PA is submitted. Enrollment takes under 10 minutes online.

Step 6. Receive and store your medication. Praluent ships refrigerated (36, 46°F). Keep it in the original carton in your refrigerator. Do not freeze. If you need to travel, it can be kept at room temperature (up to 77°F) for up to 30 days in the original carton [1].

Step 7. Injection training. The specialty pharmacy provides video or phone-based injection training. The autoinjector or prefilled syringe is injected subcutaneously into the abdomen, thigh, or upper arm. Injection-site reactions occur in approximately 7% of patients and are usually mild [1].

Step 8. Follow-up lipid panel at 4 to 8 weeks. A repeat fasting lipid panel confirms LDL-C response. If LDL-C falls below 25 mg/dL, your prescriber may reduce the dose from 150 mg to 75 mg every 2 weeks.

Safety Profile and Contraindications Relevant to WV Prescribers

Alirocumab is generally well tolerated. The most common adverse events reported in the alirocumab prescribing information include nasopharyngitis (11.3%), injection-site reactions (7.2%), and influenza (5.7%) [1]. Neurocognitive events such as confusion or memory impairment were reported at a rate of 0.8% versus 0.7% placebo in pooled ODYSSEY trials, a difference that was not statistically significant [22].

No dose adjustment is required for mild to moderate renal impairment. Hepatic impairment data are limited; use with caution in severe hepatic disease [1]. There are no known drug-drug interactions because alirocumab is catabolized via proteolytic degradation, not CYP450 pathways [1].

Pregnancy category: alirocumab is classified FDA Pregnancy Category not assigned (post-2015 labeling uses the narrative format). Animal data show no fetal harm, but LDL cholesterol is needed for fetal development. Most guidelines recommend discontinuing PCSK9 inhibitors before conception and during pregnancy [23]. WV prescribers counseling women of reproductive age should document this discussion.